AdaptHealth
AHCONASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $7.72 Prior regular-session close from the quote source.
- $7.64–$7.93 Regular-session low and high so far today.
- 2.2M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Feb 23 projected Projected for 2027-02-23 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $5.21–$13.43 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own AHCO if reimbursement and execution stop eroding margins.
AHCO price history
Loading recent earnings…
INVESTMENT THESIS
What must happen next
AdaptHealth’s national at-home care platform remains relevant to providers and payors, so chronic home-equipment and supply demand continues to flow through its network rather than migrating to smaller local competitors, mail-order specialists, or vertically integrated payor channels.HoldingMateriality: High
GAAP annual revenue remained large and relatively stable at $3.20 billion in FY2023, $3.26 billion in FY2024, and $3.24 billion in FY2025. If the referral platform holds share, revenue stability gives management time to fix margins; if it loses relevance, cost cuts cannot protect the equity.
Watch: Major Medicare Advantage payors such as UnitedHealth or Humana steer more patients to captive, preferred, or lower-cost suppliers.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue remained large and relatively stable at $3.20 billion in FY2023, $3.26 billion in FY2024, and $3.24 billion.
Open source ↗AdaptHealth’s scale in purchasing, delivery, and reimbursement administration must offset payer rate pressure and product cost inflation; otherwise home medical equipment and supplies remain commoditized and gross economics keep compressing.WeakeningMateriality: High
GAAP annual gross profit was $624.1 million in FY2023 and $681.1 million in FY2024 before weakening in FY2025. Gross profit is the first test of whether AdaptHealth has pricing and cost power or is simply passing volume through at weaker economics.
Watch: CMS, state Medicaid programs, or Medicare Advantage plans reduce reimbursement schedules or increase prior-authorization friction.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit was $624.1 million in FY2023 and $681.1 million in FY2024 before weakening in FY2025.
Open source ↗The operating platform must convert national scale into better labor, branch, billing, and logistics efficiency; if integration complexity absorbs the scale benefit, AdaptHealth will remain a cash-generative but low-quality operator.HoldingMateriality: Medium
GAAP annual operating income recovered from a loss of $598.4 million in FY2023 to income of $263.7 million in FY2024. Operating leverage determines whether revenue stability becomes equity value or is consumed by overhead and execution costs.
Watch: Branch consolidation, billing automation, or workflow standardization fails to reduce labor and administrative cost per order.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating income recovered from a loss of $598.4 million in FY2023 to income of $263.7 million in FY2024.
Open source ↗AdaptHealth’s reimbursement and collections engine continues to turn its home-care service base into operating cash even when GAAP earnings are volatile, giving the company room to self-fund operations and balance-sheet repair.StrengtheningMateriality: Medium
GAAP annual operating cash flow increased from $373.9 million in FY2022 to $480.7 million in FY2023, $541.8 million in FY2024, and $601.8 million in FY2025. Sustained cash conversion is the main reason the equity can survive margin volatility and leverage; if collections deteriorate, the turnaround becomes much riskier.
Watch: Medicare Advantage payors increase claim denials, audits, or prior authorizations, delaying or reducing collections.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow increased from $373.9 million in FY2022 to $480.7 million in FY2023, $541.8 million in FY2024.
Open source ↗Management must use cash generation to reduce financial risk rather than pursue value-destructive expansion, because the balance sheet leaves limited room for another margin or reimbursement shock.StrengtheningMateriality: Medium
Total liabilities declined from $3.06 billion at FY2022 year-end to $3.04 billion at FY2023 year-end, $2.91 billion at FY2024 year-end, and $2.79 billion at FY2025 year-end. If liabilities keep falling, more cash flow can accrue to shareholders; if leverage rises or refinancing tightens, creditors capture much of the business value.
Watch: Management resumes debt-funded acquisitions before demonstrating durable margin recovery.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Total liabilities declined from $3.06 billion at FY2022 year-end to $3.04 billion at FY2023 year-end, $2.91 billion at FY2024 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
AdaptHealth’s national at-home care platform remains relevant to providers and payors, so chronic home-equipment and supply demand continues to flow through its network rather than migrating to smaller local competitors, mail-order specialists, or vertically integrated payor channels. If the referral platform holds share, revenue stability gives management time to fix margins; if it loses relevance, cost cuts cannot protect the equity.
AdaptHealth’s scale in purchasing, delivery, and reimbursement administration must offset payer rate pressure and product cost inflation; otherwise home medical equipment and supplies remain commoditized and gross economics keep compressing. Gross profit is the first test of whether AdaptHealth has pricing and cost power or is simply passing volume through at weaker economics.
The operating platform must convert national scale into better labor, branch, billing, and logistics efficiency; if integration complexity absorbs the scale benefit, AdaptHealth will remain a cash-generative but low-quality operator. Operating leverage determines whether revenue stability becomes equity value or is consumed by overhead and execution costs.
AdaptHealth’s reimbursement and collections engine continues to turn its home-care service base into operating cash even when GAAP earnings are volatile, giving the company room to self-fund operations and balance-sheet repair. Sustained cash conversion is the main reason the equity can survive margin volatility and leverage; if collections deteriorate, the turnaround becomes much riskier.
Management must use cash generation to reduce financial risk rather than pursue value-destructive expansion, because the balance sheet leaves limited room for another margin or reimbursement shock. If liabilities keep falling, more cash flow can accrue to shareholders; if leverage rises or refinancing tightens, creditors capture much of the business value.
All standing thesis claims
Original report summary
reimbursement and execution stop eroding margins.
Bull case and bear case
Bull case and bear case for AdaptHealth
Where the evidence on AdaptHealth disagrees: Mixed on the latest evidence (Nov 3, 2026). Of its 5 thesis points, 2 strengthening, 2 holding and 1 weakening.
Bull case: what the evidence supports
AdaptHealth’s national at-home care platform remains relevant to providers and payors, so chronic home-equipment and supply demand continues to flow through its network rather than migrating to smaller local competitors, mail-order specialists, or vertically integrated payor channels.
The operating platform must convert national scale into better labor, branch, billing, and logistics efficiency; if integration complexity absorbs the scale benefit, AdaptHealth will remain a cash-generative but low-quality operator.
AdaptHealth’s reimbursement and collections engine continues to turn its home-care service base into operating cash even when GAAP earnings are volatile, giving the company room to self-fund operations and balance-sheet repair.
Management must use cash generation to reduce financial risk rather than pursue value-destructive expansion, because the balance sheet leaves limited room for another margin or reimbursement shock.
Bear case: what the evidence questions
AdaptHealth’s scale in purchasing, delivery, and reimbursement administration must offset payer rate pressure and product cost inflation; otherwise home medical equipment and supplies remain commoditized and gross economics keep compressing.
Thesis-Break Engine
Thesis-break watch · AdaptHealth
Loading the break-condition record for AdaptHealth.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
No assessed change was returned in this research window. That can reflect a quiet period or a coverage limit.
RISKS / FALSIFIERS
What could break the thesis
- Major Medicare Advantage payors such as UnitedHealth or Humana steer more patients to captive, preferred, or lower-cost suppliers.
- CMS, state Medicaid programs, or Medicare Advantage plans reduce reimbursement schedules or increase prior-authorization friction.
- Branch consolidation, billing automation, or workflow standardization fails to reduce labor and administrative cost per order.
- Medicare Advantage payors increase claim denials, audits, or prior authorizations, delaying or reducing collections.
- Management resumes debt-funded acquisitions before demonstrating durable margin recovery.
AHCO news
Loading headlines…
FINANCIAL STATEMENTS
AHCO income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
AHCO: quick answers
- When does AdaptHealth (AHCO) report earnings next?
- AdaptHealth's next results are projected for February 23, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 3, 2026. Earnings calendar
- What is AHCO's short interest?
- As of October 30, 2026, 10.9M AHCO shares were sold short, 8.00% of its shares outstanding, up 6.8% from the count before. At the stock's average daily volume that is 5.2 days to cover. FINRA publishes the count twice a month. AHCO short interest history
- Have members of Congress traded AHCO?
- Reports made public in the last 90 days disclose 2 trades in AHCO by 1 filer: 1 purchase and 1 sale. They are filed under the STOCK Act by members of Congress, the President and senior officials. Every disclosed AHCO trade
